Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

KalVista Pharmaceuticals (KALV) Cash from Investing Activities (2016 - 2025)

Historic Cash from Investing Activities for KalVista Pharmaceuticals (KALV) over the last 10 years, with Q2 2025 value amounting to -$3.3 million.

  • KalVista Pharmaceuticals' Cash from Investing Activities rose 9736.26% to -$3.3 million in Q2 2025 from the same period last year, while for Apr 2025 it was -$43.7 million, marking a year-over-year increase of 4844.25%. This contributed to the annual value of $91.0 million for FY2025, which is 20744.23% up from last year.
  • According to the latest figures from Q2 2025, KalVista Pharmaceuticals' Cash from Investing Activities is -$3.3 million, which was up 9736.26% from $48.7 million recorded in Q4 2024.
  • Over the past 5 years, KalVista Pharmaceuticals' Cash from Investing Activities peaked at $48.7 million during Q4 2024, and registered a low of -$126.2 million during Q2 2024.
  • Over the past 3 years, KalVista Pharmaceuticals' median Cash from Investing Activities value was $19.6 million (recorded in 2023), while the average stood at -$316000.0.
  • Per our database at Business Quant, KalVista Pharmaceuticals' Cash from Investing Activities soared by 7044.75% in 2024 and then surged by 9736.26% in 2025.
  • KalVista Pharmaceuticals' Cash from Investing Activities (Quarter) stood at $28.6 million in 2023, then soared by 70.45% to $48.7 million in 2024, then crashed by 106.84% to -$3.3 million in 2025.
  • Its Cash from Investing Activities was -$3.3 million in Q2 2025, compared to $48.7 million in Q4 2024 and $37.2 million in Q3 2024.